A similar safety profile was also reported for the G-protein biassed agonist MM07 (Brame et al., 2015) and the small molecule agonist (Winkle et al., 2023) as well as for [Pyr1] apelin in obesity (Castan-Laurell et al., 2008) and patients with heart failure (Japp et al., 2010). Here, APLN is linked to heart failure.